Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease

doi:10.4239/wjd.v16.i6.104706

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (321)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

HTML

132

Figures (1-2)

Tables (1-2)

Sum=233

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=78

Publishing Process of This Article

Item

Count

Browse

Download

Sum=3

Jun 15, 2025 (publication date) through Jun 16, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Jun 15, 2025; 16(6): 104706
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.104706

Open in New Tab Full Size Figure Download Figure

Figure 1 Proposed mechanisms of action of Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease. SGLT2: Sodium-glucose cotransporter 2; GFR: Glomerular filtration rate. The Figure was generated using elements from Servier Medical Art, which are licensed under a Creative Commons Attribution 4.0 license.

Open in New Tab Full Size Figure Download Figure

Figure 2 Systemic role of glucagon-like peptide-1 and effects of receptor agonists. GLP-1: Glucagon-like peptide-1; GLP-1 RAs: Glucagon-like peptide-1 receptor agonists; eGFR: Estimated glomerular filtration rate. The Figure was generated using elements from Servier Medical Art, which are licensed under a Creative Commons Attribution 4.0 license.

Citation: Santos GL, dos Santos CF, Rocha GR, Calmon MS, Lemos FF, Silva LG, Luz MS, Pinheiro SL, Botelho AC, de Melo FF. Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease. World J Diabetes 2025; 16(6): 104706
URL: https://www.wjgnet.com/1948-9358/full/v16/i6/104706.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i6.104706